MZL
MCID: MRG003
MIFTS: 52

Marginal Zone B-Cell Lymphoma (MZL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 12 15 37 17 70
Marginal Zone Lymphoma 12 20 58
Mucosa-Associated Lymphoid Tissue Lymphoma 70
Mzl 20

Characteristics:

Orphanet epidemiological data:

58
marginal zone lymphoma
Prevalence: 1-9/100000 (France),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050748
UMLS via Orphanet 71 C0242647
Orphanet 58 ORPHA300912
UMLS 70 C0242647 C1367654

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to primary cutaneous marginal zone b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Fludarabine and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous marginal zone b-cell lymphoma 33.3 MALT1 IRF4 BCL10
2 nodal marginal zone b-cell lymphoma 33.1 MALT1 BCL6
3 splenic marginal zone lymphoma 32.9 MALT1 CD5 BIRC3 BCL6
4 nodal marginal zone lymphoma 32.4 SPN MME KDM4C IRF4 IGHV4-38-2 CD5
5 b-cell lymphoma 31.8 MYD88 MME MIR142 MALT1 IRF4 CD5
6 lymphoma 31.7 MYD88 MALT1 IRF4 CD5 CD19 CCR6
7 lymphoma, mucosa-associated lymphoid type 31.6 TNFAIP3 SPN SIGLEC5 MYD88 MME MIR142
8 follicular lymphoma 31.5 MME IRF4 CD5 BCL6 BCL10
9 lymphoproliferative syndrome 31.4 CD5 CD40LG CCR6 BCL6
10 plasmacytoma 31.4 IRF4 CD79A CD5
11 composite lymphoma 31.1 MME IGHV4-38-2 CD79A CD5 BCL6
12 gastric lymphoma 31.1 MALT1 IRF4 IGHV4-38-2 CD79A BIRC3 BCL6
13 peripheral t-cell lymphoma 31.0 MME CD5 CD19 BCL6
14 mantle cell lymphoma 30.9 SPN MME MALT1 CD5 CD40LG CD19
15 primary cutaneous diffuse large b-cell lymphoma, leg type 30.9 MYD88 IRF4
16 orbit lymphoma 30.9 MALT1 BIRC3 BCL10
17 lung lymphoma 30.9 SPN MME MALT1 CD79A CD5 BCL6
18 cryoglobulinemia, familial mixed 30.8 CD5 CD40LG
19 sjogren syndrome 30.8 TNFAIP3 CD79A CD40LG
20 gamma heavy chain disease 30.8 MYD88 IGHV4-38-2
21 cryoglobulinemia 30.7 CD79A CD5 CD40LG
22 heavy chain disease 30.7 MYD88 IGHV4-38-2 CD79A
23 central nervous system lymphoma 30.7 MYD88 MALT1 CCR6 BCL6
24 syphilis 30.7 CD79A CD40LG CCR6
25 secondary syphilis 30.7 CD79A CD40LG
26 monoclonal paraproteinemia 30.7 IGHV4-38-2 CD79A CD19
27 anemia, autoimmune hemolytic 30.6 IGHV4-38-2 CD5 CD40LG CD19 CCR6 C1S
28 mulchandani-bhoj-conlin syndrome 30.6 MME CD40LG CD19 CCR6
29 t-cell/histiocyte rich large b cell lymphoma 30.6 MME BCL6
30 intestinal disease 30.5 MIR142 KDM4C CCR6 BCL6
31 toxoplasmosis 30.5 MYD88 CD79A CD40LG
32 bladder lymphoma 30.5 SPN MME CD79A CD5 BCL6
33 cll/sll 30.5 SPN MME IGHV4-38-2 CD79A CD5 CD19
34 agammaglobulinemia 30.4 CD79A CD40LG CD19
35 gastrointestinal lymphoma 30.4 SPN MME MALT1 CD79A CD5 BCL6
36 breast lymphoma 30.4 SPN MME IRF4 CD79A CD5 BCL6
37 t-cell adult acute lymphocytic leukemia 30.4 IRF4 CD5 CCR6 CARD11
38 mature t-cell and nk-cell lymphoma 30.4 MME KDM4C CD79A CD5 CCR6 BCL6
39 burkitt lymphoma 30.4 MME IRF4 CD40LG CD19 BIRC3 BCL6
40 t-cell lymphoblastic leukemia/lymphoma 30.4 TNFAIP3 IRF4 CCR6 BIRC3
41 diffuse large b-cell lymphoma 30.4 TNFAIP3 SPN MYD88 MME MIR142 MALT1
42 connective tissue disease 30.3 SIGLEC5 MIR142 KDM4C CD40LG CCR6
43 lymphoplasmacytic lymphoma 30.3 MYD88 MME KDM4C IGHV4-38-2 CD79A CD5
44 waldenstroem's macroglobulinemia 30.3 MYD88 IRF4 IGHV4-38-2 CD5 CD40LG CD19
45 richter's syndrome 30.2 SPN IRF4 IGHV4-38-2 CD5 CD19
46 celiac disease 1 30.2 TNFAIP3 MYD88 CD79A CD19 CCR6
47 immune deficiency disease 30.2 SPN SIGLEC5 MIR142 CD79A CD5 CD40LG
48 b-lymphoblastic leukemia/lymphoma 30.0 MME CD19 CCR6
49 splenic disease 30.0 SIGLEC5 MYD88 IGHV4-38-2 CD5 CD19 CCR6
50 myeloma, multiple 30.0 MYD88 MIR142 KDM4C IRF4 IGHV4-38-2 CD5

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 BCL10 BIRC3 CARD11 CD40LG MYD88 TNFAIP3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BCL10 CARD11 MYD88 TNFAIP3

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 BCL10 BCL6 BIRC3 CARD11 CD19 CD40LG
2 hematopoietic system MP:0005397 10.03 BCL10 BCL6 BIRC3 CARD11 CCR6 CD19
3 immune system MP:0005387 9.86 BCL10 BCL6 BIRC3 CARD11 CCR6 CD19
4 integument MP:0010771 9.28 BCL6 CARD11 CD19 CD40LG CD5 KDM4C

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
rituximab Approved Phase 3 174722-31-7 10201696
4
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
5 Antineoplastic Agents, Immunological Phase 3
6 Antirheumatic Agents Phase 3
7 Immunologic Factors Phase 3
8
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
10
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
11
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
12
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
13
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
15
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
16
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
17
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
18
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
19
Epirubicin Approved Phase 2 56420-45-2 41867
20
Etoposide Approved Phase 2 33419-42-0 36462
21
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
22
Ifosfamide Approved Phase 2 3778-73-2 3690
23
Lenalidomide Approved Phase 2 191732-72-6 216326
24
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
25
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
26
Clarithromycin Approved Phase 2 81103-11-9 84029
27
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
28
Gemcitabine Approved Phase 2 95058-81-4 60750
29
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
30
ofatumumab Approved Phase 2 679818-59-8 6918251
31
Oprelvekin Approved, Investigational Phase 1, Phase 2 145941-26-0
32
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
33
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
34
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
35
Veltuzumab Investigational Phase 1, Phase 2 728917-18-8
36
Navitoclax Investigational Phase 1, Phase 2 923564-51-6
37 Bryostatin 1 Investigational Phase 2 83314-01-6
38
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
39 Complement System Proteins Phase 2
40 Gastrointestinal Agents Phase 2
41 Antiemetics Phase 2
42 Adjuvants, Immunologic Phase 2
43 Interleukin-12 Phase 2
44 Tubulin Modulators Phase 2
45 Antimitotic Agents Phase 2
46 Methylprednisolone Acetate Phase 2
47
Isophosphamide mustard Phase 2 100427
48 Etoposide phosphate Phase 2
49 Angiogenesis Inhibitors Phase 2
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
2 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
3 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
4 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma Recruiting NCT04212013 Phase 3 Ibrutinib;Rituximab
5 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Recruiting NCT04680052 Phase 3 tafasitamab;rituximab;lenalidomide;placebo
6 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Parsaclisib Plus Investigator's Choice of Either Rituximab or Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma Not yet recruiting NCT04796922 Phase 3 parsaclisib;rituximab;obinutuzumab
7 Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone Unknown status NCT01514344 Phase 2 intralesional rituximab
8 A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Unknown status NCT01678404 Phase 2 131I-rituximab
9 A Prospective Single Arm Trial of Involved Field Radiotherapy Alone for Stage I-II Low Grade Non-gastric Marginal Zone Lymphoma Unknown status NCT00377195 Phase 2
10 Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma Unknown status NCT01516606 Phase 2 clarithromycin, oral, high dose
11 A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma Unknown status NCT03093831 Phase 2 Ibrutinib
12 A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma Completed NCT00596804 Phase 1, Phase 2 veltuzumab
13 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
14 A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Completed NCT00406809 Phase 1, Phase 2 ABT-263
15 Radiation Therapy Alone for Stage 1 and 2 MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma Completed NCT04465162 Phase 2
16 A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) Completed NCT02433795 Phase 2 bendamustine plus rituximab
17 A Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus (RAD001) in Marginal Zone B-cell Lymphomas (MZL) EudraCT Number 2009-011725-14 Completed NCT01164267 Phase 2 Everolimus
18 A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas Completed NCT02254772 Phase 1, Phase 2 SD-101
19 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
20 A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant Completed NCT00058305 Phase 2 bryostatin 1;vincristine sulfate
21 Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma Completed NCT00026182 Phase 2
22 R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma Completed NCT01213095 Phase 2 rituximab
23 A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Completed NCT01068392 Phase 2 Oxaliplatin, Prednisolone
24 Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142) Completed NCT00210327 Phase 2 Bortezomib (drug)
25 A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma Completed NCT00711828 Phase 2 Bortezomib;Cyclophosphamide;Dexamethasone
26 A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and R/R Indolent Lymphoma Completed NCT03520920 Phase 2 Zanubrutinib;Rituximab
27 A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Completed NCT01980628 Phase 2 ibrutinib
28 Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma Completed NCT00453102 Phase 2 Rituximab;Ibritumomab Tiuxetan
29 A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma Completed NCT00253630 Phase 2 Vorinostat
30 MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Recruiting NCT03697512 Phase 2 Ibrutinib;Rituximab
31 A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma Recruiting NCT04433156 Phase 2 Bortezomib;Rituximab;Epirubicin;Cyclophosphamide;Prednisone
32 Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1) Recruiting NCT03474744 Phase 2 Copanlisib
33 Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response Recruiting NCT04508647 Phase 2 Ublituximab;Umbralisib
34 Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1) Recruiting NCT03322865 Phase 2 Obinutuzumab
35 A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma Recruiting NCT04298879 Phase 2 IBI376
36 A Phase 2, Open-Label Study of Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma Recruiting NCT04189952 Phase 2 Acalabrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide
37 A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Recruiting NCT03797456 Phase 2 ICP-022
38 A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study) Recruiting NCT03768505 Phase 2 Zandelisib (ME-401)
39 A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Recruiting NCT03919175 Phase 2 Umbralisib;Rituximab
40 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study Active, not recruiting NCT02853370 Phase 2 Bendamustine and Rituximab
41 A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Active, not recruiting NCT01808599 Phase 2 Chlorambucil;Rituximab i.v.;Rituximab s.c.
42 A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma Active, not recruiting NCT03846427 Phase 2 Zanubrutinib
43 International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitoring and Antibiotic Re-treatment at Infection Re-occurrence in Patients With Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) Active, not recruiting NCT01820910 Phase 2 Doxycycline
44 An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma Active, not recruiting NCT02532257 Phase 2 Ibrutinib;Lenalidomide
45 A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma Active, not recruiting NCT03031483 Phase 2 clarithromycin and lenalidomide
46 A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204) Active, not recruiting NCT03144674 Phase 2 Parsaclisib
47 A Phase II Trial of Combination of Oral Lenalidomide and Low-dose Cyclophosphamide for Patients With Antibiotics-unresponsive Extranodal Marginal Zone B-cell Lymphoma Not yet recruiting NCT04604028 Phase 2 Lenalidomide [Leavdo®]
48 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Not yet recruiting NCT04416451 Phase 2 Rituximab;Venetoclax
49 Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL) Not yet recruiting NCT04646395 Phase 2 Tafasitamab;Acalabrutinib
50 A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma Not yet recruiting NCT04110301 Phase 1, Phase 2 Recombinant Humanized Monoclonal Antibody MIL62 Injection;Lenalidomide

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

40
Bone Marrow, Bone, Breast, Thyroid, Liver, Lung, B Cells

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 2859)
# Title Authors PMID Year
1
Distribution of CD1a-positive cells is not different between pseudolymphomatous folliculitis and primary cutaneous marginal zone lymphoma. 61
33326629 2021
2
Umbralisib: First Approval. 61
33797740 2021
3
Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). 61
33476433 2021
4
Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma. 61
33794083 2021
5
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. 61
33314017 2021
6
Case report of primary dural lymphoma mimicking a cerebellar meningioma and brief review of literature. 61
31301042 2021
7
A case of primary cutaneous B-cell lymphoma with immature features in an old man. Diffuse large B-cell lymphoma with immature features or B-cell lymphoblastic lymphoma? 61
32623764 2021
8
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives. 61
33687623 2021
9
The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. 61
33806113 2021
10
The limited role of comprehensive staging work-up in ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type (MALToma) with excellent prognosis. 61
33779995 2021
11
Biophysical Analysis of Acute and Late Toxicity of Radiotherapy in Gastric Marginal Zone Lymphoma-Impact of Radiation Dose and Planning Target Volume. 61
33808548 2021
12
Masson Trichrome and Sulfated Alcian Blue Stains Distinguish Light Chain Deposition Disease From Amyloidosis in the Lung. 61
33002919 2021
13
Primary cutaneous follicle center lymphoma with extensive plasmacytic differentiation and t(14;18) in both the lymphoid and plasma cell components. 61
33786907 2021
14
Clinicopathological aspects of primary mucosa-associated lymphoid tissue lymphoma of the salivary gland: A retrospective single-center analysis of 72 cases. 61
33730431 2021
15
A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review. 61
33730924 2021
16
Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. 61
33803501 2021
17
Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma. 61
33788720 2021
18
[A study of LEF1 protein expression in diagnosis and differential diagnosis of lymphoblastic lymphoma/acute lymphoblastic leukemia]. 61
33677883 2021
19
VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. 61
33682304 2021
20
Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease. 61
33775999 2021
21
Dermoscopic and trichoscopic features of primary cutaneous lymphomas - systematic review. 61
33710688 2021
22
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. 61
33539729 2021
23
The Secondary Manifestation of a Marginal Zone Lymphoma in the Larynx: Lessons From a Misdiagnosis. 61
33758705 2021
24
Genome-wide DNA methylation analysis along the progression of gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type. 61
33590882 2021
25
Development and validation of a prognostic nomogram for gastric marginal zone lymphoma: a Surveillance, Epidemiology and End Results-based population study. 61
33401980 2021
26
Endobronchial Extranodal Marginal Zone B-Cell Lymphoma with Plasmacytic Differentiation. 61
33728124 2021
27
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. 61
33560394 2021
28
A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. 61
33054119 2021
29
Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma. 61
33475146 2021
30
Improved primary staging of marginal zone lymphoma by addition of CXCR4-directed PET/CT. 61
33579803 2021
31
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. 61
33670870 2021
32
Primary IgG4-producing extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the cavernous sinus: A mimicker of IgG4-related disease/hypertrophic pachymeningitis. 61
33524189 2021
33
Peripheral blood morphology review and diagnostic proficiency evaluation by a new Spanish EQAS during the period 2011-2019. 61
32870604 2021
34
Primary marginal zone B-cell lymphoma of the cavernous sinus: a case report and review of the literature. 61
33579209 2021
35
Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. 61
33739787 2021
36
A Case Report of Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma With Plasmacytic Differentiation. 61
33606375 2021
37
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 61
33145711 2021
38
Whole brain radiation therapy for primary central nervous system marginal zone lymphoma: a case report. 61
33489698 2021
39
Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. 61
33399228 2021
40
Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas. 61
33727844 2021
41
Imaging of head and neck mucosa-associated lymphoid tissue lymphoma (MALToma). 61
33436095 2021
42
Regression of Marginal Zone Lymphoma After Praziquantel Therapy in a Patient With Remote Schistosoma haematobium Infection. 61
33509726 2021
43
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. 61
32520760 2021
44
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. 61
33496731 2021
45
Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. 61
33495148 2021
46
Epidemiology of Non-Hodgkin's Lymphoma. 61
33573146 2021
47
MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. 61
33575225 2021
48
Primary Pulmonary B-Cell Lymphoma: A Review and Update. 61
33499258 2021
49
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. 61
33570635 2021
50
Primary cutaneous lymphomas in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A series of 12 cases. 61
33415780 2021

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNFAIP3 SIGLEC5 MYD88 MME MALT1 IRF4
2
Show member pathways
13.32 SIGLEC5 MYD88 MALT1 CD79A CD40LG CD19
3
Show member pathways
12.67 MYD88 MALT1 CD79A CD19 BCL10
4
Show member pathways
12.6 MALT1 CD79A CD19 CARD11 BCL10
5
Show member pathways
12.55 TNFAIP3 MYD88 MALT1 CD40LG CARD11 BCL10
6
Show member pathways
12.5 MALT1 CD79A CD40LG CARD11 BCL10
7
Show member pathways
12.39 MYD88 MALT1 IRF4 CD40LG CARD11 BCL10
8
Show member pathways
12.32 MALT1 CD19 CARD11 BCL6 BCL10
9
Show member pathways
12.27 MALT1 CD40LG CARD11 BCL10
10
Show member pathways
12.09 MALT1 IRF4 CD79A CD19 CARD11 BCL6
11 12.07 TNFAIP3 MALT1 CD40LG BIRC3 BCL10
12 11.84 TNFAIP3 MYD88 MALT1 IRF4 CD79A CD40LG
13
Show member pathways
11.81 MALT1 CARD11 BCL10
14 11.78 SPN MME CD79A CD5 CD19
15 11.77 MME CD5 CD19
16 11.6 SPN MME IRF4 CD19
17 11.57 CD40LG CCR6 BCL6
18 11.53 IRF4 CD40LG BCL6
19 11.52 TNFAIP3 MYD88 MALT1 CD40LG CARD11 BIRC3
20 11.28 CD79A CD40LG CD19
21 11.16 TNFAIP3 CD40LG BIRC3
22 11.01 TNFAIP3 MALT1 BCL10

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.63 MME CD79A CD19 CARD11 BIRC3 BCL10
2 external side of plasma membrane GO:0009897 9.5 SPN IGHV4-38-2 CD79A CD5 CD40LG CD19
3 polkadots GO:0002096 9.26 MALT1 BCL10
4 CBM complex GO:0032449 8.8 MALT1 CARD11 BCL10

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10 MYD88 MALT1 CD40LG BIRC3 BCL6
2 immune system process GO:0002376 9.98 MYD88 IRF4 CD79A CD19 C1S BCL6
3 regulation of apoptotic process GO:0042981 9.85 MALT1 CARD11 BIRC3 BCL6 BCL10
4 cellular response to lipopolysaccharide GO:0071222 9.84 TNFAIP3 MYD88 MALT1 BCL10
5 regulation of inflammatory response GO:0050727 9.79 MYD88 BIRC3 BCL6
6 positive regulation of protein ubiquitination GO:0031398 9.77 MALT1 BIRC3 BCL10
7 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.77 CARD11 BIRC3 BCL10
8 T cell costimulation GO:0031295 9.73 CD5 CD40LG CARD11
9 cellular defense response GO:0006968 9.72 SPN CCR6 BCL10
10 regulation of immune response GO:0050776 9.72 SPN CD40LG CD19 CARD11 BCL6
11 B cell proliferation GO:0042100 9.69 CD79A CD40LG CARD11
12 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 MYD88 MALT1 BCL10
13 positive regulation of interleukin-2 production GO:0032743 9.65 MALT1 IRF4 CARD11
14 regulation of T cell migration GO:2000404 9.58 SPN CCR6
15 regulation of T cell receptor signaling pathway GO:0050856 9.58 MALT1 BCL10
16 response to fungus GO:0009620 9.57 MALT1 BCL10
17 B cell differentiation GO:0030183 9.56 CD79A CD40LG CARD11 BCL6
18 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.55 MYD88 MALT1 CARD11 BIRC3 BCL10
19 positive regulation of T cell activation GO:0050870 9.54 MALT1 CARD11 BCL10
20 regulation of germinal center formation GO:0002634 9.52 TNFAIP3 BCL6
21 B-1 B cell differentiation GO:0001923 9.4 MALT1 CD19
22 immunoglobulin mediated immune response GO:0016064 9.13 MYD88 CD19 BCL10
23 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.02 MYD88 MALT1 CD40LG CARD11 BCL10

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 TNFAIP3 MALT1 BCL10
2 CARD domain binding GO:0050700 9.26 CARD11 BCL10
3 kinase activator activity GO:0019209 8.96 MALT1 BCL10
4 protein self-association GO:0043621 8.92 TNFAIP3 MYD88 MALT1 BCL10

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....